Identification of 2-piperidone as a biomarker of CYP2E1 activity through metabolomic phenotyping

Toxicological Sciences

Volumn 135, Issue 1, 2013, Pages 37-47

  Cheng, Jie ^a   Chen, Chi ^a,b   Kristopher, Krausz W ^a   Manna, Soumen K ^a   Scerba, Mike ^c   Friedman, Fred K ^a   Luecke, Hans ^c   Idle, Jeffrey R ^d   Gonzalez, Frank J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

2 piperidone; Biomarker; Cadaverine; CYP2E1; Metabolomics

Indexed keywords

2 PIPERIDONE; 6 HYDROXY 2 PIPERIDONE; BIOLOGICAL MARKER; CADAVERINE; CYTOCHROME P450 2E1; DRUG METABOLITE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DEGRADATION; FEMALE; GENOTYPE; IN VITRO STUDY; LIVER CELL; MALE; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; METABOLOME; MOUSE; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PROTEIN EXPRESSION; WILD TYPE;

2-PIPERIDONE; BIOMARKER; CADAVERINE.; CYP2E1; METABOLOMICS;

ANIMALS; BIOLOGICAL MARKERS; CADAVERINE; CYTOCHROME P-450 CYP2E1; FEMALE; METABOLOMICS; MICE; PHENOTYPE; PIPERIDONES; TANDEM MASS SPECTROMETRY;

EID: 84883204566     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kft143     Document Type: Article

References (35)

1. Abdelmegeed, M. A., Banerjee, A., Yoo, S. H., Jang, S., Gonzalez, F. J., and Song, B. J. (2012). Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis. J. Hepatol. 57, 860-866.
2. Aubert, J., Begriche, K., Knockaert, L., Robin, M. A., and Fromenty, B. (2011). Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: Mechanisms and pathophysiological role. Clin. Res. Hepatol. Gastroenterol. 35, 630-637.
3. Bardocz, S. (1993). The role of dietary polyamines. Eur. J. Clin. Nutr. 47, 683-690.
4. Bondoc, F. Y., Bao, Z., Hu, W. Y., Gonzalez, F. J., Wang, Y., Yang, C. S., and Hong, J. Y. (1999). Acetone catabolism by cytochrome P450 2E1: Studies with CYP2E1-null mice. Biochem. Pharmacol. 58, 461-463.
5. Callery, P. S., and Geelhaar, L. A. (1984). Biosynthesis of 5-aminopentanoic acid and 2-piperidone from cadaverine and 1-piperideine in mouse. J. Neurochem. 43, 1631-1634.
6. Caro, A. A., and Cederbaum, A. I. (2004). Oxidative stress, toxicology, and pharmacology of CYP2E1. Annu. Rev. Pharmacol. Toxicol. 44, 27-42.
7. Catanzaro, I., Naselli, F., Saverini, M., Giacalone, A., Montalto, G., and Caradonna, F. (2012). Cytochrome P450 2E1 variable number tandem repeat polymorphisms and health risks: a genotype-phenotype study in cancers associated with drinking and/or smoking. Mol. Med. Report 6, 416-420.
8. Chen, C., Gonzalez, F. J., and Idle, J. R. (2007). LC-MS-based metabolomics in drug metabolism. Drug Metab. Rev. 39, 581-597.
9. Chen, C., Krausz, K. W., Idle, J. R., and Gonzalez, F. J. (2008). Identification of novel toxicity-associated metabolites by metabolomics and mass isotopomer analysis of acetaminophen metabolism in wild-type and Cyp2e1-null mice. J. Biol. Chem. 283, 4543-4559.
10. Cheung, C., Yu, A. M., Ward, J. M., Krausz, K. W., Akiyama, T. E., Feigenbaum, L., and Gonzalez, F. J. (2005). The cyp2e1-humanized transgenic mouse: Role of cyp2e1 in acetaminophen hepatotoxicity. Drug Metab. Dispos. 33, 449-457.
11. Emery, M. G., Jubert, C., Thummel, K. E., and Kharasch, E. D. (1999). Duration of cytochrome P-450 2E1 (CYP2E1) inhibition and estimation of functional CYP2E1 enzyme half-life after single-dose disulfiram administration in humans. J. Pharmacol. Exp. Ther. 291, 213-219.
12. Ernstgård, L., Johanson, G., Karlsson, A. S., and Warholm, M. (2007). Phenotyping of cytochrome P450 2E1 in vitro and in vivo. Curr. Drug Metab. 8, 493-498.
13. Ernstgård, L., Warholm, M., and Johanson, G. (2004). Robustness of chlorzoxazone as an in vivo measure of cytochrome P450 2E1 activity. Br. J. Clin. Pharmacol. 58, 190-200.
14. Gonzalez, F. J. (2005). Role of cytochromes P450 in chemical toxicity and oxidative stress: Studies with CYP2E1. Mutat. Res. 569, 101-110.
15. Guengerich, F. P., and Cheng, Q. (2011). Orphans in the human cytochrome P450 superfamily: Approaches to discovering functions and relevance in pharmacology. Pharmacol. Rev. 63, 684-699.
16. Johnson, C. H., Patterson, A. D., Idle, J. R., and Gonzalez, F. J. (2012). Xenobiotic metabolomics: Major impact on the metabolome. Annu. Rev. Pharmacol. Toxicol. 52, 37-56.
17. Jones, J. P., Joswig-Jones, C. A., Hebner, M., Chu, Y., and Koop, D. R. (2011). The effects of nitrogen-heme-iron coordination on substrate affinities for cytochrome P450 2E1. Chem. Biol. Interact. 193, 50-56.
18. Jurikova, T., Rop, O., Mlcek, J., Sochor, J., Balla, S., Szekeres, L., Hegedusova, A., Hubalek, J., Adam, V., and Kizek, R. (2011). Phenolic profile of edible honeysuckle berries (genus lonicera) and their biological effects. Molecules 17, 61-79.
19. Lee, K. S., and Kim, S. K. (2013). Direct and metabolism-dependent cytochrome P450 inhibition assays for evaluating drug-drug interactions. J. Appl. Toxicol. 33, 100-108.
20. Lee, S. S., Buters, J. T., Pineau, T., Fernandez-Salguero, P., and Gonzalez, F. J. (1996). Role of CYP2E1 in the hepatotoxicity of acetaminophen. J. Biol. Chem. 271, 12063-12067.
21. León-Buitimea, A., Rodríguez-Fragoso, L., Lauer, F. T., Bowles, H., Thompson, T. A., and Burchiel, S. W. (2012). Ethanol-induced oxidative stress is associated with EGF receptor phosphorylation in MCF-10A cells overexpressing CYP2E1. Toxicol. Lett. 209, 161-165.
22. Li, J., Wei, D. Q., Wang, J. F., Yu, Z. T., and Chou, K. C. (2012). Molecular dynamics simulations of CYP2E1. Med. Chem. 8, 208-221.
23. Lu, D., Yu, X., and Du, Y. (2011). Meta-analyses of the effect of cytochrome P450 2E1 gene polymorphism on the risk of head and neck cancer. Mol. Biol. Rep. 38, 2409-2416.
24. Mahjoub, A., Hochlaf, M., Poisson, L., Nieuwjaer, N., Lecomte, F., Schermann, J. P., Geŕgoire, G., Manil, B., Garcia, G. A., and Nahon, L. (2011). Slow photoelectron spectroscopy of d-valerolactam and its dimer. Chemphyschem 12, 1822-1832.
25. Naila, A., Flint, S., Fletcher, G., Bremer, P., and Meerdink, G. (2010). Control of biogenic amines in food-existing and emerging approaches. J. Food Sci. 75, R139-R150.
26. Reeves, P. G. (1997). Components of the AIN-93 diets as improvements in the AIN-76A diet. J. Nutr. 127(5 Suppl), 838S-841S.
27. Schafer, A., Galuppo, P., Fraccarollo, D., Vogt, C., Widder, J. D., Pfrang, J., Tas, P., Barbosa-Sicard, E., Ruetten, H., Ertl, G., et al. (2010). Increased cytochrome P4502E1 expression and altered hydroxyeicosatetraenoic acid formation mediate diabetic vascular dysfunction: rescue by guanylyl-cyclase activation. Diabetes 59, 2001-2009.
28. Schantz, M., Erk, T., and Richling, E. (2010). Metabolism of green tea catechins by the human small intestine. Biotechnol. J. 5, 1050-1059.
29. Seglen, P. O. (1976). Preparation of isolated rat liver cells. Methods Cell Biol. 13, 29-83.
30. Seiler, N. (2004). Catabolism of polyamines. Amino Acids 26, 217-233.
31. Sinclair, P. R., Gorman, N., Walton, H. S., Bement, W. J., Szakacs, J., Gonzalez, F. J., Dalton, T. P., Nebert, D. W., and Sinclair, J. F. (2000). Relative roles of CYP2E1 and CYP1A2 in mouse uroporphyria caused by acetone. Arch. Biochem. Biophys. 384, 383-390.
32. Sotsuka, T., Sasaki, Y., Hirai, S., Yamagishi, F., and Ueno, K. (2011). Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients. In Vivo 25, 803-812.
33. Trafalis, D. T., Panteli, E. S., Grivas, A., Tsigris, C., and Karamanakos, P. N. (2010). CYP2E1 and risk of chemically mediated cancers. Expert Opin. Drug Metab. Toxicol. 6, 307-319.
34. Urpi-Sarda, M., Monagas, M., Khan, N., Lamuela-Raventos, R. M., Santos- Buelga, C., Sacanella, E., Castell, M., Permanyer, J., and Andres-Lacueva, C. (2009). Epicatechin, procyanidins, and phenolic microbial metabolites after cocoa intake in humans and rats. Anal. Bioanal. Chem. 394, 1545-1556.
35. Vesell, E. S., and Korsunsky, Z. (1998). Pedigree analysis of a subject with abnormally slow renal elimination of 6-hydroxychlorzoxazone. Pharmacology 56, 262-266.